(NASDAQ: VRCA) Verrica Pharmaceuticals's forecast annual revenue growth rate of 64.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.24%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.27%.
Verrica Pharmaceuticals's revenue in 2026 is $30,829,000.On average, 7 Wall Street analysts forecast VRCA's revenue for 2026 to be $272,193,184, with the lowest VRCA revenue forecast at $186,004,686, and the highest VRCA revenue forecast at $348,758,786. On average, 6 Wall Street analysts forecast VRCA's revenue for 2027 to be $552,718,618, with the lowest VRCA revenue forecast at $279,007,029, and the highest VRCA revenue forecast at $747,340,256.
In 2028, VRCA is forecast to generate $1,436,032,096 in revenue, with the lowest revenue forecast at $945,833,828 and the highest revenue forecast at $1,943,084,666.